Welcome to our dedicated page for Harrow Health news (Ticker: HROW), a resource for investors and traders seeking the latest updates and insights on Harrow Health stock.
Company Overview
Harrow Health Inc (HROW) is an innovative eyecare pharmaceutical company focused on addressing unmet medical needs through the discovery, development, production, and commercialization of specialized ophthalmic formulations and therapeutic products across the United States. Operating at the intersection of advanced research and clinical application, the company brings together deep industry expertise, rigorous R&D, and a commitment to improving patient care.
Business Model and Operations
At its core, Harrow Health provides a comprehensive portfolio that blends ophthalmology-based drug development with non-intravenous sedation and anesthesia therapeutics for a variety of medical procedures. Its operations are structured around:
- Ophthalmic Therapeutics: Focusing on the management of ocular surface diseases, the company develops topical eye drop formulations that serve both preventative and therapeutic roles.
- Compounded Medications: Offering both sterile and non-sterile formulations, it meets the needs of physicians seeking tailored solutions for diverse clinical scenarios.
- Non-Intravenous Sedation: Developing products designed to facilitate conscious sedation during procedures such as cataract surgery, thereby enhancing patient comfort and procedural efficiency.
This multi-pronged approach not only diversifies its product portfolio but also creates a resilient business model that appeals to healthcare professionals and institutions across outpatient, in-office, and hospital settings.
Market Position and Competitive Landscape
Harrow Health Inc has carved a niche within the highly regulated US pharmaceutical market. Its strategic focus on ocular and sedation therapeutics differentiates it from broader scale pharmaceutical companies, while its commitment to advanced research and quality production standards reinforces its reputation among eyecare professionals. In a competitive landscape where precision and safety are paramount, Harrow Health’s integration of clinical insights with innovative drug formulations positions it as a noteworthy player devoted to addressing specific medical challenges effectively.
Product Portfolio and Therapeutic Solutions
The company has developed an extensive range of products that address conditions related to the ocular surface and procedural sedation. Its portfolio includes:
- Topical Ophthalmic Formulations: Designed to manage diseases affecting the ocular surface and support rehabilitation of vision-related functions.
- Compounded Medications: Both sterile and non-sterile, these are tailored to meet precise medical requirements across various treatment settings.
- Sedation Therapeutics: Products intended for sublingual administration provide non-intravenous sedation, enabling safe and effective patient management during surgical procedures.
Research, Development, and Quality Assurance
The foundation of Harrow Health Inc’s operations lies in robust research and development. The company continually refines its product offerings through comprehensive clinical research and adherence to stringent quality assurance protocols. Its approach underscores a commitment to safety and efficacy while addressing the evolving needs of healthcare providers and patients. This rigorous scientific methodology exemplifies the company’s dedication to maintaining high standards of regulatory compliance and industry best practices.
Commitment to Scientific Integrity and Patient Care
Across its diverse operations, Harrow Health demonstrates a sustained commitment to improving patient outcomes. The company’s emphasis on continuous innovation, strategic R&D, and quality-focused manufacturing processes helps ensure that its pharmaceutical solutions not only meet but often exceed industry benchmarks. This dedication to scientific integrity and patient well-being has established Harrow Health as a trusted entity within the field of eyecare therapeutics.
Strategic Value Proposition
Harrow Health Inc’s value proposition is rooted in its specialized expertise in ophthalmic formulations and sedation therapies. By addressing critical gaps in current medical treatments, the company supports healthcare providers in delivering effective and accessible care. Its balanced focus on innovation, quality, and clinical relevance positions it as a vital contributor to the pharmaceutical landscape, particularly within the realms of eye care and procedural sedation.
Overall, Harrow Health Inc exemplifies a dedicated, research-driven approach to pharmaceutical development that leverages deep industry expertise to meet unmet medical needs. Through its integrated operations and commitment to quality, it remains a significant, unbiased source of therapeutic solutions for healthcare professionals nationwide.
Harrow Health (NASDAQ: HROW) reported a record revenue of $22.1 million for Q1 2022, marking a 43% increase from $15.4 million in Q1 2021. The gross profit reached $16.2 million, up 38% year-over-year. A total of 689,000 product units were shipped, a 72% increase from the prior year. Despite a net loss of $2.4 million, the company anticipates a strong year driven by organic growth and plans for AMP-100's FDA review on October 16, 2022. Cash and equivalents stood at $42 million as of March 31, 2022.
Melt Pharmaceuticals announced favorable top-line results from its phase 1 PK study of MELT-210, a 3 mg sublingual midazolam tablet. The study involving 23 patients compared MELT-210 with IV midazolam and achieved concentration goals. CEO Larry Dillaha expressed optimism about the results, viewing it as a milestone for an IV-free sedation option. The next step includes discussions with the FDA regarding further clinical development. MELT-210 utilizes Catalent's proprietary Zydis® technology, with no FDA-approved equivalent products.
NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow Health, Inc. (NASDAQ: HROW) announced participation in B. Riley Securities' Annual Neuro & Ophthalmology Investor Conference. CEO Mark L. Baum and CFO Andrew Boll will present virtually on April 27, 2022, at 2:00 p.m. ET. A live webcast will be accessible on Harrow's website, with a replay available post-event. Harrow Health focuses on ophthalmic healthcare, owning ImprimisRx and Visionology, and holds equity in Eton Pharmaceuticals, Surface Ophthalmics, and Melt Pharmaceuticals.
Harrow Health, Inc. (Nasdaq: HROW) will release its financial results for Q1 2022 on May 5, 2022, post market close. The company, which focuses on ophthalmic healthcare, will also host a conference call at 4:45 PM ET to discuss the results and provide a business update. A webcast will be available for replay until August 5, 2022. Details of the event, including participation dial-ins and replay options, can be found on their website. This update is pertinent for investors and stakeholders tracking financial performance and corporate developments.
Harrow Health, Inc. (HROW) has appointed Perry J. Sternberg and Dr. Marty Makary to its Board of Directors, effective immediately, while Robert J. Kammer has resigned. Sternberg brings extensive commercial experience from leading eye care companies, and his expertise in strategic marketing is expected to aid in launching new FDA-approved products like AMP-100. Dr. Makary, with a strong background in healthcare policy and innovation, aligns with the company's mission of making medicines accessible. This restructuring aims to strengthen governance and support Harrow's goal of becoming a leading U.S. eye care company.
Harrow Health, Inc. (NASDAQ: HROW) reported record revenues of $20.2 million for Q4 2021, marking a 38% increase year-over-year. Gross profit also reached $15.1 million, a 42% rise, with a gross margin of 75%. The FDA accepted the NDA for AMP-100 with a PDUFA target date of October 16, 2022. Commissions from DEXYCU® sales hit $1.0 million, driven by record unit volumes. The company ended 2021 with $42.2 million in cash and equivalents, providing a strong foundation for future growth.
Melt Pharmaceuticals announces the appointment of Brad Osborne as Chief Financial Officer, bringing over 20 years of finance experience, including a decade at Precigen. His expertise spans IPOs, M&A, and SEC compliance. Dr. Larry Dillaha, CEO, emphasizes Osborne's significant role in guiding the company through its ongoing Phase 2 efficacy study for MELT-300 and advancing their patented MELT technology. Melt focuses on non-intravenous and non-opioid sedation solutions, carved out from Harrow Health in 2019, catering to over 100 million medical procedures in the U.S.
Harrow Health (NASDAQ: HROW), an ophthalmic healthcare company, will report its financial results for Q4 and the full year 2021 on March 10, 2022, after market close. A conference call is scheduled for 4:45 p.m. ET the same day to discuss results and provide business updates. Investors can access the Letter to Stockholders on the company's website following the earnings release. Harrow Health focuses on ophthalmic pharmaceuticals through its subsidiaries, ImprimisRx and Visionology.
Harrow Health, Inc. (Nasdaq: HROW) announced that the FDA has accepted its New Drug Application (NDA) for AMP-100, aimed at ocular surface anesthesia. The application has a PDUFA date of October 16, 2022.
CEO Mark L. Baum emphasized that if approved, AMP-100 would be the first non-opioid ophthalmic drug of its kind in the U.S. Harrow Health is committed to making this innovative drug commercially available to ophthalmologists and surgery centers nationwide.
Harrow Health, Inc. (NASDAQ: HROW), a healthcare company focused on ophthalmology, announced that CEO Mark L. Baum and CFO Andrew Boll will present at the Aegis Capital Corp. Virtual Conference from February 23-25, 2022. Their presentation is scheduled for February 24, 2022, at 3:30 p.m. ET. To view the presentation, attendees can access the link on Harrow Health's website in the events section. Harrow Health operates ImprimisRx and Visionology, and holds equity positions in Eton Pharmaceuticals, Surface Ophthalmics, and Melt Pharmaceuticals.
FAQ
What is the current stock price of Harrow Health (HROW)?
What is the market cap of Harrow Health (HROW)?
What is Harrow Health Inc's primary focus?
What types of products does the company offer?
How does Harrow Health Inc generate revenue?
What differentiates Harrow Health from its competitors?
In which market does Harrow Health primarily operate?
What role does research and development play in the company?
How does the company support clinical practices?
Can you explain the company’s approach to quality assurance?
